In pMMR/MSS colon cancer, neoadjuvant BOT+BAL met the trial’s primary endpoint with a 36% major pathologic response rate, including 29% pathologic complete response, within an overall 71% pathologic ...

UNICORN Challenges Immunotherapy Resistance in MSS Colon Cancer / Agenus, Balstilimab, botensilimab, cancer, Colon cancer, colorectal cancer, ctDNA, Filippo ...

For patients with colorectal liver metastases (CRLM), laparoscopic liver resection (LLR) is associated with lower postoperative morbidity than open liver resection (OLR), with similar long-term ...

Using an intestinal ultrasound may help patients avoid having to undergo invasive procedures, like colonoscopies, as often.